David J. Behm
GlaxoSmithKline
56 Papers
499 Citations
David J. Behm is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Urotensin-II receptor & Receptor. The author has an hindex of 26, co-authored 54 publications.
Chat about Author
Papers
Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2
Robert N. Willette,Weike Bao,Sandhya S. Nerurkar,Tian-Li Yue,Chris P. Doe,Gerald Stankus,Gregory H. Turner,Haisong Ju,Heath Thomas,Cindy E. Fishman,Anthony Sulpizio,David J. Behm,Sandra J. Hoffman,Zuojun Lin,Irina M. Lozinskaya,Linda N. Casillas,Min Lin,Robert E. Lee Trout,Bartholomew J. Votta,Kevin S. Thorneloe,Erin S. R. Lashinger,David J. Figueroa,Robert W. Marquis,Xiaoping Xu +23 more
TL;DR: In summary, inappropriate activation of TRPV4 produces acute circulatory collapse associated with endothelial activation/injury and failure of the pulmonary microvascular permeability barrier.
291
Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities
Chris P. Doe,Ross G. Bentley,David J. Behm,Robert Lafferty,Robert A. Stavenger,David Kendall Jung,Mark James Bamford,Terry Panchal,Eugene T. Grygielko,Lois L. Wright,Gary K. Smith,Zunxuan Chen,Christine Webb,Sanjay S. Khandekar,Tracey Yi,Robert B. Kirkpatrick,Edward Dul,Larry J. Jolivette,Joseph P. Marino,Robert N. Willette,Dennis Lee,Erding Hu +21 more
TL;DR: Two aminofurazan-based ROCK inhibitors are characterized, GSK269962A and SB-772077-B, as members of a novel class of compounds that potently inhibit ROCK enzymatic activity and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.
171
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Krista B. Goodman,Haifeng Cui,Sarah E. Dowdell,Dimitri E. Gaitanopoulos,Robert L. Ivy,Clark A. Sehon,Robert A. Stavenger,Gren Z. Wang,Andrew Q. Viet,Weiwei Xu,Guosen Ye,Simon Semus,Christopher P. Evans,Harvey E. Fries,Larry J. Jolivette,Robert B. Kirkpatrick,Edward Dul,Sanjay S. Khandekar,Tracey Yi,David Kendallc Jung,Lois L Wright,Gary K Smith,David J. Behm,Ross Bentley,Christopher P. Doe,Erding Hu,Dennis Lee +26 more
TL;DR: Indazole substitution played a critical role in decreasing clearance and improving oral bioavailability and a series of dihydropyridones were discovered, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.
158
In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor
Patricia L. Podolin,Brian Bolognese,Joseph F. Foley,Edward Long,Brian Peck,Sandra Umbrecht,Xiaojun Zhang,Penny Zhu,Benjamin Schwartz,Wensheng Xie,Chad Quinn,Hongwei Qi,Sharon Sweitzer,Stephanie Chen,Marc Galop,Yun Ding,Svetlana L. Belyanskaya,David I. Israel,Barry A. Morgan,David J. Behm,Joseph P. Marino,Edit Kurali,Mary S. Barnette,Ruth J. Mayer,Catherine Booth-Genthe,James F. Callahan +25 more
TL;DR: The data indicate that GSK2256294A attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resolution, and would be an appropriate agent to evaluate the role of sEH in clinical studies, for example in diseases where cigarette smoke is a risk factor.
109
Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Weike Bao,David J. Behm,Sandhya S. Nerurkar,Zhaohui Ao,Ross G. Bentley,Rosanna C. Mirabile,Douglas G. Johns,Tina N Woods,Christopher P. Doe,Robert W. Coatney,Jason F Ohlstein,Stephen A. Douglas,Robert N. Willette,Tian-Li Yue +13 more
TL;DR: The results suggest that Ang II induced hypertension, organ damage, and ROS production are possibly mediated by p38 MAPK and inhibition of p38MAPK may offer a therapeutic approach for cardiovascular disease.
94